Acute hepatitis after riluzole administration

Remy, André‐Jean; Camu, William; Ramos, Jeanne; Larrey, Dominique

doi:10.1016/s0168-8278(99)80115-9

Cited by 33 publications

(8 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All five cases with elevated liver enzyme (5.4%) showed elevated ALT and AST levels, whereas only two cases showed elevated γ-GTP levels; this trend is consistent with previously reported trends [4, 15]. A study investigating dose-dependent effects of riluzole has suggested that hepatotoxicity reflects metabolic toxicity of riluzole [15, 17]. In this study, all cases with elevated liver enzymes that discontinued riluzole presented a history of medication for diabetes or hyperlipidemia (Tables 2 and 3); this may reflect increased metabolic ability.…”

Section: Discussionsupporting

confidence: 87%

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

et al. 2019

View full text Add to dashboard Cite

Background Riluzole is the only approved oral drug for amyotrophic lateral sclerosis (ALS). We performed a retrospective study including ALS patients treated with riluzole, focusing on adverse events. Methods Patients diagnosed with ALS according to the revised El Escorial criteria (World Federation of Neurology) in our center and who were administered 50 mg oral riluzole twice daily between January 2011 and September 2017 and followed up for at least 6 months from treatment initiation or until death were included. Data regarding sex, age, disease type, initial symptoms, biochemical analyses performed before and after riluzole administration, and medical history were collected. In case of withdrawal, cause of discontinuation and durations of disease and drug administration were recorded. Results A total of 92 cases were enrolled. Riluzole administration was discontinued in 20 cases (21.7%). The most frequent reason for discontinuation was elevated liver enzymes ( n = 5, 5.4%), followed interstitial pneumonia (IP), nausea and appetite loss, dizziness, general malaise, tongue paresthesia, and urinary urgency. In two cases, administration was discontinued primarily because of progression of bulbar palsy. All adverse events occurred within 6 months from treatment initiation and improved soon after its discontinuation. Three IP cases developed severe respiratory failure and required steroid treatment. Conclusion Riluzole administration was discontinued in 20 cases among total of 92 cases. Careful follow-up is important for the first six months after the initiation of riluzole administration, including through interviews, chemical analyses, and chest X-rays, as required.

show abstract

Section: Discussionsupporting

confidence: 87%

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Acute hepatitis has been reported rarely at usual doses of riluzole, in one case recurring with rechallenge (Remy et al 1999).…”

Section: Adverse Effectsmentioning

confidence: 98%

Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder

Grant

Song

Swedo

2010

Journal of Child and Adolescent Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…Elevated liver function tests usually resolved spontaneously, and were an uncommon reason for discontinuing therapy in the phase III trial. Idiosyncratic events reported in the literature include acute hepatitis and jaundice [148,149]. Importantly both toxicities resolved completely following withdrawal of riluzole therapy.…”

Section: Adverse Effects and Toxicitymentioning

confidence: 98%

Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis

Cheah

Vucic²,

Krishnan³

et al. 2010

CMC

230

146

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS) is a universally fatal neurodegenerative disease of the human motor system. Aetiological mechanisms implicated in the development of ALS have been linked to the glutamatergic neurotransmitter system, with destruction of motor neurons triggered through excessive activation of glutamate receptors at the synaptic cleft. This 'excitotoxicity' theory of ALS gave rise to the development of therapeutic approaches and ultimately clinical trials involving riluzole, initially thought to act solely as an inhibitor of glutamate release. Subsequent effects of riluzole have been postulated to include indirect antagonism of glutamate receptors, in addition to inactivation of neuronal voltage-gated Na+ channels. Riluzole remains the only disease-modifying therapy available to patients with ALS. Despite having been clinically available since the mid-1990 s, the in vivo pharmacological targets of riluzole have been poorly defined. An improved understanding concerning the potential neuroprotective mechanisms of riluzole may unearth pathophysiological processes that mediate neurodegeneration in ALS. The present review summarises the known chemical and pharmacological properties of riluzole. The failure of other putative neuroprotective therapies to demonstrate positive treatment outcomes in this intractable disease will be reviewed. Finally, the hypothesis that Na+ conductances may be involved in the processes of neuronal and axonal degeneration in ALS will be explored.

show abstract

Acute hepatitis after riluzole administration

Cited by 33 publications

References 9 publications

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

Interstitial pneumonia and other adverse events in riluzole-administered amyotrophic lateral sclerosis patients: a retrospective observational study

Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder

Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis

Contact Info

Product

Resources

About